These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 35038377)

  • 41. Identification of clinical predictors for dupilumab dose spacing in adults with atopic dermatitis: a real-world study.
    Chiricozzi A; Dal Bello G; Gori N; Di Nardo L; Schena D; Caldarola G; Maurelli M; De Simone C; Girolomoni G; Peris K
    J Dermatolog Treat; 2023 Dec; 34(1):2235041. PubMed ID: 37449324
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of dupilumab in pediatric patients with moderate to severe atopic dermatitis: a real-world study.
    Yang DY; Li L; Lu T; Jing WW; Liu X; Li XL
    Arch Dermatol Res; 2023 Apr; 315(3):467-472. PubMed ID: 35989340
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk Factors for Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
    Treister AD; Kraff-Cooper C; Lio PA
    JAMA Dermatol; 2018 Oct; 154(10):1208-1211. PubMed ID: 30167653
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis.
    Fargnoli MC; Esposito M; Ferrucci S; Girolomoni G; Offidani A; Patrizi A; Peris K; Costanzo A; Malara G; Pellacani G; Romanelli M; Amerio P; Cristaudo A; Flori ML; Motolese A; Betto P; Patruno C; Pigatto P; Sirna R; Stinco G; Zalaudek I; Bianchi L; Boccaletti V; Cannavò SP; Cusano F; Lembo S; Mozzillo R; Gallo R; Potenza C; Rongioletti F; Tiberio R; Grieco T; Micali G; Persechino S; Pettinato M; Pucci S; Savi E; Stingeni L; Romano A; Argenziano G;
    J Dermatolog Treat; 2021 Aug; 32(5):507-513. PubMed ID: 31647347
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Application of Dupilumab to Pediatric Patients Aged 6-11yrs with Moderate-to-Severe Atopic Dermatitis Whose Disease is Not Adequately Controlled: The Clinical Data so Far.
    Balboul S; Kahn J; Tracy A; Peacock A; Cline A
    Drug Des Devel Ther; 2023; 17():1323-1327. PubMed ID: 37152103
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Facial dermatoses and use of protective mask during Covid-19 pandemic: A clinical and psychological evaluation in patients affected by moderate-severe atopic dermatitis under treatment with dupilumab.
    Vanessa M; Elia E; Federica V; Edoardo C; Chiara A; Francesca G; Paola S
    Dermatol Ther; 2022 Jul; 35(7):e15573. PubMed ID: 35535633
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The efficacy and safety of dupilumab for the treatment of atopic dermatitis among Chinese patients in clinical practice: A single-center retrospective study.
    Li Y; Lu J; Chen R; Wang Y; Ding Y; Xu S; Zou Y; Yi X; Shi Y
    Dermatol Ther; 2022 May; 35(5):e15385. PubMed ID: 35174593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis.
    Eichenfield LF; Bieber T; Beck LA; Simpson EL; Thaçi D; de Bruin-Weller M; Deleuran M; Silverberg JI; Ferrandiz C; Fölster-Holst R; Chen Z; Graham NMH; Pirozzi G; Akinlade B; Yancopoulos GD; Ardeleanu M
    Am J Clin Dermatol; 2019 Jun; 20(3):443-456. PubMed ID: 31066001
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
    Deleuran M; Thaçi D; Beck LA; de Bruin-Weller M; Blauvelt A; Forman S; Bissonnette R; Reich K; Soong W; Hussain I; Foley P; Hide M; Bouaziz JD; Gelfand JM; Sher L; Schuttelaar MLA; Wang C; Chen Z; Akinlade B; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Staudinger H; Graham NMH; Pirozzi G; Ardeleanu M
    J Am Acad Dermatol; 2020 Feb; 82(2):377-388. PubMed ID: 31374300
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis.
    Beck LA; Thaçi D; Hamilton JD; Graham NM; Bieber T; Rocklin R; Ming JE; Ren H; Kao R; Simpson E; Ardeleanu M; Weinstein SP; Pirozzi G; Guttman-Yassky E; Suárez-Fariñas M; Hager MD; Stahl N; Yancopoulos GD; Radin AR
    N Engl J Med; 2014 Jul; 371(2):130-9. PubMed ID: 25006719
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.
    O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R
    Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dupilumab for the treatment of atopic dermatitis: A clinical trial review.
    McGregor S; Farhangian ME; Feldman SR
    Expert Opin Biol Ther; 2015; 15(11):1657-60. PubMed ID: 26428945
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial.
    Paller AS; Simpson EL; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Soong W; Gonzalez ME; Schneider LC; Sidbury R; Lockshin B; Meltzer S; Wang Z; Mannent LP; Amin N; Sun Y; Laws E; Akinlade B; Dillon M; Kosloski MP; Kamal MA; Dubost-Brama A; Patel N; Weinreich DM; Yancopoulos GD; O'Malley JT; Bansal A;
    Lancet; 2022 Sep; 400(10356):908-919. PubMed ID: 36116481
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.
    Simpson EL; Bieber T; Guttman-Yassky E; Beck LA; Blauvelt A; Cork MJ; Silverberg JI; Deleuran M; Kataoka Y; Lacour JP; Kingo K; Worm M; Poulin Y; Wollenberg A; Soo Y; Graham NM; Pirozzi G; Akinlade B; Staudinger H; Mastey V; Eckert L; Gadkari A; Stahl N; Yancopoulos GD; Ardeleanu M;
    N Engl J Med; 2016 Dec; 375(24):2335-2348. PubMed ID: 27690741
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Is dupilumab effective in adult-onset atopic dermatitis: Real-life experience of 16 patients.
    Erbağcı E; Demirel Öğüt N; Koç Yıldırım S; Hapa FA
    J Cosmet Dermatol; 2022 Oct; 21(10):4852-4857. PubMed ID: 35100490
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study.
    Patruno C; Napolitano M; Argenziano G; Peris K; Ortoncelli M; Girolomoni G; Offidani A; Ferrucci SM; Amoruso GF; Rossi M; Stingeni L; Malara G; Grieco T; Foti C; Gattoni M; Loi C; Iannone M; Talamonti M; Stinco G; Rongioletti F; Pigatto PD; Cristaudo A; Nettis E; Corazza M; Guarneri F; Amerio P; Esposito M; Belloni Fortina A; Potenza C; Fabbrocini G;
    J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):958-964. PubMed ID: 33332697
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dupilumab therapy in atopic dermatitis is safe during COVID-19 infection era: A systematic review and meta-analysis of 1611 patients.
    El-Qushayri AE; Mahmoud MA; Salman S; Sarsik S; Nardone B
    Dermatol Ther; 2022 Jun; 35(6):e15476. PubMed ID: 35357060
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis.
    Patruno C; Potestio L; Fabbrocini G; Napolitano M
    Dermatol Ther; 2022 Dec; 35(12):e15933. PubMed ID: 36227462
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis.
    Yosipovitch G; de Bruin-Weller M; Armstrong A; Wu JJ; Herranz P; Thaçi D; Delevry D; Bagousse GB; Zhang R; Shumel B; Rossi AB; Chao J
    Dermatol Ther (Heidelb); 2021 Dec; 11(6):2147-2157. PubMed ID: 34714527
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment-a population-based cohort study.
    Kridin K; Schonmann Y; Solomon A; Onn E; Bitan DT; Weinstein O; Cohen AD
    Immunol Res; 2022 Feb; 70(1):106-113. PubMed ID: 34647194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.